Abstract 5553
Background
Dermatologic adverse events (DAE) are frequently experienced in patients under sorafenib. Although the majority appear as rash or hand-foot reaction, some patients may present SL requiring biopsy or local procedures that may impact in the treatment. While there are series of patients with melanoma and BRAF inhibitors presenting SL, there is no information on HCC patients with sorafenib.
Methods
We analyzed a prospective database of patients with HCC treated with sorafenib. Patients who developed biopsed SL were included and the pathology samples were reviewed.
Results
Between oct-2007 and jan-2018, 313 patients were treated with sorafenib (54.6% BCLC-C, 88.7% ECOG-PS0 and 83.6% CPA), 88 (28.1%) presented DAE in the first 60 days (eDAE) and 24 (7.7%) developed SL submitted to excisional biopsy. From the 24 patients, 33 SL were biopsied and 5 patients presented more than 1 SL. Most of the patients with SL were male (79.2%), CPA (87.5%), HCV etiology (87.5%) and 2 had liver transplantation. The median time from sorafenib initiation until SL biopsy was 8.5 months (IQR 4.4 to 18.1). SL are described in the table. Lymphocyte proliferation at the interface between the SL and dermis was noted in 61.1%. The median treatment duration (MTD) and OS in the whole cohort were 6.5 months [IQR 3.3-13.9] and 13.6 months [CI95% 12.2- 15.6], respectively. For the subgroup with SL, the MTD and OS was 12.5 [9.5 - 22.0] and 26.5 months [CI95% 17.0 - 43.9], respectively. For those with both eDEA and SL, the MTD and OS was 17.9 months [7.7-28.9] and 26.5 [22.0-51.6] respectively. There was no permanent discontinuation related to the SL.Table: 705P
SL subtypes
| n = 33 lesions (100%) | |
|---|---|
| Tumor SL | 22 (66.7%) |
| Keratoacanthomas | 7 (21.2%) |
| Squamous cell carcinomas | 5 (15.2%) |
| Basal cell carcinomas | 3 (9.1%) |
| Seborrheic queratosis | 3 (9.1%) |
| Hypertrophic keratoma | 1 (3%) |
| Sebaceous hyperplasia | 1 (3%) |
| Pilomatrixioma | 1 (3%) |
| Trichilemmal cyst | 1 (3%) |
| Non-Tumor SL | 7 (21.2) |
| Suppurative folliculitis | 2 (6.1%) |
| Interphase dermatitis | 2 (6.1%) |
| Subacute spongiform dermatitis | 1 (3%) |
| Septal panniculitis/ Erythema nodosum | 1 (3%) |
| Lichen planus | 1 (3%) |
| Livedo reticularis | 2 (6.1%) |
| Thrombotic vasculopathy | 1 (3%) |
| Epi/Hypodermic necrosis | 1 (3%) |
Conclusions
This is the largest series on patients with HCC and sorafenib that presented biopsed SL. Similar to other tumors treated with BRAF inhibitors, patients with HCC and sorafenib are in risk of developing SL. Interestingly, the majority presented lymphocyte proliferation. This reinforces the need to understand the immune modulation by sorafenib.
Clinical trial identification
Legal entity responsible for the study
BCLC group.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4784 - Tranilast inhibits TGF-beta-induced EMT and invasion/metastasis via the suppression of Smad4 in lung cancer cell lines.
Presenter: Koji Takahashi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
767 - Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro
Presenter: Alexander Cortez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
938 - MiR-449a suppresses endometrial cancer invasion and metastasis by targeting NDRG1
Presenter: Lihua Qiu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4866 - Cancer-associated fibroblasts-derived VEGFA mediates the migration of gastric cancer cells through VEGFR1
Presenter: xiaoxun Wang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4934 - Risk prediction of metastasis through study of circulating tumor cells
Presenter: Panagiotis Apostolou
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3289 - First step to metastasis: miRNAome abnormalities impair cell-cell adhesion and facilitate detachment of breast cancer cells
Presenter: Volodymyr Halytskiy
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4110 - Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment
Presenter: Alexandra Tsidulko
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1526 - Study of the activation of TLR receptors in neurospheres from glioblastoma cells in vitro
Presenter: David Albert Bellver
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4862 - 5-Fluorouracil induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients
Presenter: Zhang Min
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
635 - Thrombocytosis and leukocytosis: are they negative prognostic factors in solid tumours?
Presenter: Filip Kohutek
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract